Work

Phase I safety and immunogenicity study of NY-ESO-1b peptide and Montanide ISA-51 vaccination of patients with ovarian cancer (OC) in high risk first remission

Year: 2006

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2006.24.18_suppl.5078

Authors: C. S. Magid Diefenbach, P. Sabbatini, C. Aghajanian, D. Spriggs, H. Lee, S. Pezzulli, A. A. Jungbluth, L. J. Old, S. Gnjatic, J. Dupont

Institutions: Memorial Sloan Kettering Cancer Center, Ludwig Cancer Research

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2603934902

Cites:

Cited by:

Related to: 10